Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series.

ABSTRACT:

Objectives

Anakinra is a selective IL-1 inhibitor, which has been used in the context of secondary haemophagocytic lymphohistiocytosis. Although usually given in the s.c. form, previous anecdotal reports have emphasized its utility when given i.v. Our aim is to report our experience on the beneficial effects of anakinra i.v. in patients with SARS-CoV-2 and evidence of hyperinflammation.

Methods

We report four patients with severe COVID-19 infection requiring intensive care admission and ventilatory support.

Results

All four patients showed evidence of deterioration, with hyperferritinaemia and increasing oxygen requirements and with superadded bacterial infections. Upon commencement of anakinra i.v., there was subsequent improvement in the patients clinically, with re

SUBMITTER: Clark KEN 

PROVIDER: S-EPMC7454860 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature